Details for New Drug Application (NDA): 217892
✉ Email this page to a colleague
The generic ingredient in POTASSIUM PHOSPHATES is potassium phosphate, dibasic; potassium phosphate, monobasic. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the potassium phosphate, dibasic; potassium phosphate, monobasic profile page.
Summary for 217892
| Tradename: | POTASSIUM PHOSPHATES |
| Applicant: | Cipla |
| Ingredient: | potassium phosphate, dibasic; potassium phosphate, monobasic |
| Patents: | 0 |
Pharmacology for NDA: 217892
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Suppliers and Packaging for NDA: 217892
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| POTASSIUM PHOSPHATES | potassium phosphate, dibasic; potassium phosphate, monobasic | SOLUTION;INTRAVENOUS | 217892 | ANDA | Cipla USA Inc. | 69097-055 | 69097-055-97 | 25 VIAL in 1 CARTON (69097-055-97) / 50 mL in 1 VIAL (69097-055-67) |
| POTASSIUM PHOSPHATES | potassium phosphate, dibasic; potassium phosphate, monobasic | SOLUTION;INTRAVENOUS | 217892 | ANDA | Cipla USA Inc. | 69097-077 | 69097-077-97 | 25 VIAL in 1 CARTON (69097-077-97) / 15 mL in 1 VIAL (69097-077-67) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML) | ||||
| Approval Date: | Jan 24, 2025 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML) | ||||
| Approval Date: | Jan 24, 2025 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML) | ||||
| Approval Date: | Jan 24, 2025 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
